Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

BIOTRONIK Releases Line-Extension of Orsiro Hybrid Drug Eluting Stent

Published: Tuesday, September 03, 2013
Last Updated: Tuesday, September 03, 2013
Bookmark and Share
The highly deliverable Orsiro stent is now available in lengths up to 40 mm to address a wider range of lesions.

BIOTRONIK has announced the market release of new 35 and 40 mm versions of Orsiro, the industry’s first hybrid DES (Drug Eluting Stent) featuring a bioabsorbable polymer. BIOTRONIK now offers one of the longest drug-eluting stents on the market across all diameters.

The Orsiro 40 mm was first implanted by Dr. Heinz-Joachim Büttner, MD of University Heart Center, Bad Krozingen, Germany. "The low strut thickness and good deliverability of Orsiro is even more evident in long lengths,” commented Dr. Büttner "With the addition of the new sizes, there is now an Orsiro available for almost every case."

The efficacy and safety of Orsiro was recently demonstrated in two high profile studies, BIOFLOW-II and BIOFLOW-III, which showed that Orsiro performs as best in class.

The robust clinical evidence of the BIOFLOW-II study was presented at the 2013 EuroPCR congress by principal investigator, Prof. Stephan Windecker, MD of University Hospital Bern, Switzerland.

BIOFLOW-II is a prospective, international, multi-center, randomized trial which evaluated the safety and efficacy of Orsiro compared to Abbott’s XIENCE PRIME™.

At nine months, the results for the primary endpoint in-stent late lumen loss were 0.10 ±0.32 mm in the Orsiro arm and 0.11 ±0.29 mm in the XIENCE PRIME™ arm evaluated by an independent core laboratory and confirming the non-inferiority hypothesis (p-value for non-inferiority <0.0001).

No significant differences were reported for the clinical end-points at nine months. Additionally no stent thrombosis was reported in either arm.

“With the addition of the 35 and 40 mm lengths, Orsiro now has a complete size range. The new lengths, in combination with the great deliverability, means that physicians can use Orsiro across a wider range of lesions,“ commented Alain Aimonetti, Vice President Sales and Business Development, BIOTRONIK Vascular Intervention.

Aimonetti continued, “The impressive results from the BIOFLOW-II and BIOFLOW-III trials demonstrate the excellent performance of Orsiro and firmly place it at the forefront of the stent market.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Approves First Single-Lead ICD with Atrial Sensing
BIOTRONIK’s Lumax DX system could help the 50,000 patients each year who may benefit from atrial sensing, without pacing indication.
Tuesday, September 17, 2013
BIOTRONIK Orsiro Hybrid DES Lives Up to Abbott’s XIENCE PRIME™
Positive 9 month results from BIOFLOW-II clinical trial and 12 month results from BIOFLOW-III registry presented at EuroPCR congress.
Tuesday, July 09, 2013
BIOTRONIK Home Monitoring® Reduces Inappropriate ICD Shocks by 52%
ECOST trial results published in European Heart Journal.
Friday, December 21, 2012
BIOTRONIK Announces 12-Month Results from 4EVER Study
Results show strong evidence of benefits for lower limb intervention when using Pulsar stents.
Monday, November 19, 2012
First CRT-D Patient Enrolled in the EuroEco ICD/CRT-D Trial
Study to assess the economic effects of BIOTRONIK Home Monitoring®.
Tuesday, July 24, 2012
Large-Scale BIOTRONIK SPIRIT-ICD Study Enrollment Complete
SPIRIT-ICD study explores benefits of intensified diagnostic follow-up and timely therapeutic intervention for high-risk patient group.
Monday, July 09, 2012
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos